0000000000218962

AUTHOR

Valentin Bourgeois

showing 4 related works from this author

Germline JAK2 L611S mutation in a child with thrombocytosis

2018

GeneticsThrombocytosisThrombocytosisPlatelet CountInfantHematologyExonsBiologyJanus Kinase 2medicine.diseaseGermline03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisMutation (genetic algorithm)MutationmedicineHumansOnline Only ArticlesGerm-Line Mutation030215 immunology
researchProduct

High HFE mutation incidence in idiopathic erythrocytosis.

2018

0301 basic medicinemedicine.medical_specialtybusiness.industryIncidence (epidemiology)IncidenceHematologyPolycythemiaGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisInternal medicineMutation (genetic algorithm)MutationmedicineHumansIdiopathic erythrocytosisbusinessHemochromatosis ProteinBritish journal of haematology
researchProduct

Diagnosis of exon 12‐positive polycythemia vera rescued by NGS

2020

Abstract A JAK2V617F‐negative polycythemia associated with low serum epo needs to be tested for an exon 12 JAK2 mutation. When negative, due to potential serious complications in PV, a next generation sequencing is necessary to rule out false negative results.

lcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematologyDNA sequencing03 medical and health sciencesExon0302 clinical medicinePolycythemia veraExon 12polycythemia verahemic and lymphatic diseasesmedicineerythrocytosisnext generation sequencinglcsh:R5-920business.industryJak2 mutationlcsh:RGeneral Medicinemedicine.diseaseVirologyJAK2030220 oncology & carcinogenesisbusinesslcsh:Medicine (General)Clinical Case Reports
researchProduct

Interest of exome sequencing trio-like strategy based on pooled parental DNA for diagnosis and translational research in rare diseases.

2021

Abstract Background Exome sequencing (ES) has become the most powerful and cost‐effective molecular tool for deciphering rare diseases with a diagnostic yield approaching 30%–40% in solo‐ES and 50% in trio‐ES. We applied an innovative parental DNA pooling method to reduce the parental sequencing cost while maintaining the diagnostic yield of trio‐ES. Methods We pooled six (Agilent‐CRE‐v2–100X) or five parental DNA (TWIST‐HCE–70X) aiming to detect allelic balance around 8–10% for heterozygous status. The strategies were applied as second‐tier (74 individuals after negative solo‐ES) and first‐tier approaches (324 individuals without previous ES). Results The allelic balance of parental‐pool v…

Genetic MarkersCost effectivenessTranslational researchBiologyQH426-470Sensitivity and SpecificityWorkflowTranslational Research Biomedicalchemistry.chemical_compoundsymbols.namesakeExome SequencingFalse positive paradoxGeneticsHumansDna poolingGenetic Predisposition to DiseaseGenetic TestingAlleleMolecular BiologyGenetics (clinical)Exome sequencingtrio‐like strategy; parental‐pool strategyGeneticsSanger sequencingcost effectivenessReproducibility of Resultsrare diseasesSequence Analysis DNAOriginal ArticleschemistryResearch DesignsymbolsOriginal ArticleDNAGenome-Wide Association StudyMolecular geneticsgenomic medicine
researchProduct